Novo Nordisk is under pressure from competitors in the consumer drug market, leading to a drop in its stock price.
Novo Nordisk reported better-than-expected quarterly results and raised its full-year forecast. However, investors were not convinced that the company would be able to return to a sustainable growth path despite the increasing competitive pressure from Eli Lilly, CNBC reported.
Novo Nordisk reported better-than-expected quarterly results and raised its full-year forecast. However, investors were not convinced that the company would be able to return to a sustainable growth path despite the growing pressure from Eli Lilly, according to CNBC.
